
Daily Pill May Work as Well as Ozempic for Weight Loss and Blood Sugar
A daily pill may be as effective in lowering blood sugar and aiding weight loss in people with Type 2 diabetes as the popular injectable drugs Mounjaro and Ozempic, according to results of a clinical trial announced by Eli Lilly on Thursday morning.
The drug, orforglipron, is a GLP-1, a class of drugs that have become blockbusters because of their weight-loss effects. But GLP-1s are expensive, must be kept refrigerated and must be injected. A pill that produces similar results has the potential to become far more widely used.
'In the coming decades, 700 million people around the world will have Type 2 diabetes, and over a billion will have obesity,' said Dr. Daniel Skovronsky, Lilly's chief scientific officer. 'Injections cannot be the solution for billions of people around the world.'
The results Lilly announced came from a clinical trial involving 559 people with Type 2 diabetes who took the new pill or a placebo for 40 weeks. In patients who took orforglipron, blood sugar levels fell by 1.3 to 1.6 percent, about the same amount in that time period experienced by patients taking Ozempic and Mounjaro in unrelated trials. For 65 percent of people taking the new pill, blood sugar levels dropped into the normal range.
Patients on the new pill also lost weight — up to 16 pounds without reaching a plateau at the study's end. Their weight loss was similar to that achieved in 40 weeks with Ozempic but slightly less than with Mounjaro in unrelated trials.
Side effects were the same as those with the injectable obesity drugs — diarrhea, indigestion, constipation, nausea and vomiting.
This was the first of seven large clinical trials of orforglipron to report results. Some of the others are testing the drug for weight loss in people without diabetes.
The company said it would present these new results at the annual meeting of the American Diabetes Association's Scientific Sessions in June and will publish them in a peer-reviewed journal.
Lilly added that it would seek approval from the Food and Drug Administration later this year to market orforglipron for obesity and early in 2026 for diabetes.
If the drug is approved for obesity and diabetes, Dr. Skovronsky said, the company is confident it will have sufficient amounts of the pills to meet demand. He said that he had learned the results of the diabetes study on Tuesday morning but that without even knowing them, the company had been preparing supplies. It has built factories and has already made a billion pills.
Twelve percent of American adults say they have taken a GLP-1. About 40 percent of Americans are obese, and more than 10 percent have diabetes, most of whom have Type 2, according to the Centers for Disease Control and Prevention.
In a way, the very existence of orforglipron is a triumph of modern chemistry. The injectable GLP-1 drugs are peptides — small fragments of proteins. (GLP stands for glucagon-like peptide.) Peptides are digested by the stomach. So, in order to make an oral GLP-1, chemists had to find a way to make a nonpeptide that acts exactly like a peptide. Researchers at Chugai Pharmaceutical Company, a Japanese company, figured out a way, licensing their drug to Lilly in 2018.
The solution was to find a small molecule — thousandths of the size of a peptide — that sinks into a tiny pocket in the protein that is the target for GLP-1s. When it sinks into the pocket, the protein changes shape just as it does when a GLP-1 binds to the whole protein.
Finding that small molecule, Dr. Skovronsky said, was 'the holy grail.'
The result — a pill that can be taken at any time of day, with or without food — is almost unheard-of in the world of peptide drugs. Insulin, probably the most common peptide drug, has been around for more than 50 years. It is still only an injectable despite intense efforts by scientists to make an insulin pill. So is human growth hormone. So are drugs used to treat a wide variety of diseases, including arthritis and cancer.
Novo Nordisk has a GLP-1 pill, Rybelsus, but it contains the GLP-1 peptide, so it must be taken in large doses and is not as effective as the injectables because most of it is digested.
But for patients with diabetes and those struggling with obesity, a pill that can replace an injection can be transformative, for several reasons.
One is that it can make treatments attractive to those who cannot bear very idea of injecting themselves.
Dr. C. Ronald Kahn, a professor of medicine at Harvard and chief academic officer at Harvard's Joslin Diabetes Center, said he had many patients who were reluctant to inject themselves with Ozempic or Mounjaro.
A pill, he said, 'would definitely be preferred by most people.'
Dr. Sean Wharton, director of the Wharton Medical Clinic in Burlington, Ontario, has a broader hope. Dr. Wharton, who enrolled patients in Lilly's study of orforglipron for obesity, said a pill could potentially bring GLP-1 treatment to underserved populations throughout the world.
'It can be easily made in a factory and shipped everywhere,' he said. It should cost much less to make than peptides and does not require packaging in special injection pens. It does not have to be kept refrigerated.
For now, only rich countries have had access to GLP-1 drugs, and even in those countries, the drugs are available only to a small portion of people.
'Here we have a chance of a medicine being given to millions and millions of people,' Dr. Wharton said.
But that depends on Eli Lilly and how it chooses to price and distribute its drug.
'That's why I emphasize the word 'chance,'' Dr. Wharton said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
RFK Jr. Bombarded Bill Nye With Endless Anti-Vax Text Screeds
Robert F. Kennedy Jr. sent a flood of texts to Bill Nye trying to convince the beloved 'Science Guy' of his anti-vax claims. The old text chain, sent before Kennedy became Donald Trump's health secretary, was revealed by Nye during a Men's Health profile of the children's television presenter. The barrage of messages from the prominent vaccine skeptic, which the magazine described as 'miles and miles of texts,' contained numerous links to articles and websites peddling vaccine-autism conspiracies that Nye said he paid no real attention to. 'Just no self-awareness,' Nye said. 'And if you read these articles he sent, they're all this speculation about autism and just cause-and-effect, and mercury in vaccines, that maybe there's a connection. I wrote him back and said, 'Okay, I'll read your book. I think you've confused causation with correlation. Your friend, Bill.'' The stream of messages did not end there, Nye said, even after he told Kennedy, 'Okay, no more texts.' 'He started again! So I cut him off,' Nye said. 'He does not have good judgment. He is not suited for this job.' The Department of Health and Human Services did not immediately respond to a request for comment from the Daily Beast. Kennedy has led a full-blown assault on vaccines as part of the Trump administration's campaign to restore public 'trust' in the lifesaving shots. That includes the shock move to fire all 17 members of the CDC's Advisory Committee on Immunization Practices (ACIP), an expert panel that evaluates vaccine safety and efficacy. All had been appointed under the Biden administration. In a Wall Street Journal op-ed, Kennedy said vaccines had become a 'divisive issue in American politics' and that public confidence in the health agencies that provide them is 'waning.' Nye said the increase in vaccine skepticism, which soared amid the COVID-19 pandemic, is having real life negative consequences on people's lives. That includes the reaction to a measles outbreak in Texas that primarily hit unvaccinated individuals in the Mennonite community. 'It was a religious sect with historically low vaccination rates. And the argument from the other side is: They have rights not to get vaccinated. No, you don't,' a frustrated Nye said. 'Unvaccinated people can, and usually do, spread a disease. And that's why we have these rules, for public health! It's not arbitrary. It's not about your rights. It's about my rights, people.' Nye didn't hold back on Kennedy's bizarre public stunts either—like chugging raw milk with health influencer Dr. Paul Saladino to promote the Trump administration's initially error-riddled Make America Healthy Again report on childhood illness. 'And then this thing where people want to drink raw milk. No, you don't,' Nye said. 'This is very well understood! Louis Pasteur! You guyyys! What is happening?' For more, listen to Bill Nye the Science Guy on The Last Laugh podcast.
Yahoo
an hour ago
- Yahoo
Study: Real-world results of GLP-1 drugs don't match trials
Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised by the drugs' clinical trials, a new study says. People taking such GLP-1 drugs lost just under 9% of their body weight on average after a year, researchers reported Tuesday in the journal Obesity. That's far less than the 15% to 21% body weight reduction promised by the clinical trials that led to the approval of Wegovy (semaglutide) and Zepbound (tirzepatide) for weight loss, researchers said. "Patients treated for obesity with semaglutide or trizepatide lost less weight on average in a regular clinical setting compared to what is observed in randomized clinical trial," lead investigator Hamlet Gasoyan said in a news release. He is a researcher at the Cleveland Clinic Center for Value-Based Care Research. People taking the drugs in real-world settings appear to be more likely to quit taking the meds, researchers said. They also might be prescribed lower dosages in clinical practice than were used in the drug trials. Glucagon-like peptide-1 (GLP-1) drugs mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food. For this study, researchers tracked nearly 7,900 patients being treated by the Cleveland Clinic for severe obesity, of whom about 6,100 were prescribed semaglutide and the rest tirzepatide. Average body weight loss after a year was nearly 9% for the whole group, results show. But weight loss varied based on when a person stopped taking the drugs, researchers found. Average weight loss was under 4% for those who stopped treatment early, versus nearly 7% or those who stopped later on, the study says. Those who stayed on their medications lost an average 12% body weight. Results also show that more than 4 in 5 (81%) of patients were prescribed a low maintenance dose of their GLP-1 drug, and that made a difference as well. People who stayed on their meds and received high doses lost nearly 14% of their body weight with semaglutide and 18% with tirzepatide. "Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of health care providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions," Gasoyan said. Overall, patients had higher odds of losing 10% or more of their body weight after a year if they remained on their meds, were prescribed a high dosage, were taking tirzepatide rather than semaglutide, and were female, results show. The cost of the drugs and problems were insurance were a common reason for patients stopping GLP-1 treatment, along with side effects and medication shortages, researchers said. Staying on the GLP-1 meds particularly helped the nearly 17% of patients who had prediabetes, a condition in which elevated blood sugar levels increase a person's risk of developing Type 2 diabetes. About 68% of those who stuck with their treatment wound up with normal blood sugar levels, compared with 41% who stopped taking the drugs later in the study and 33% who stopped earlier. "Type 2 diabetes is one of the most common complications of obesity, so diabetes prevention is very important," Gasoyan said. "This study highlights that treatment discontinuation, especially early, negatively affects both weight and glycemic control outcomes." A follow-up study is in the works to better track why patients stop taking their GLP-1 drugs, researchers said. More information Harvard Medical School has more on GLP-1 drugs. Copyright © 2025 HealthDay. All rights reserved.


WebMD
an hour ago
- WebMD
FDA Approves New 3-in-1 Combo Pill for High Blood Pressure
June 11, 2025 – The FDA has approved a new pill for adults with high blood pressure (hypertension) that combines three medicines in one. Available in one regular and two lower doses, it offers a convenient option for treating hypertension, which affects nearly half of the adults in the U.S. and raises their risk of stroke and heart failure. Sold as Widaplik, it is the first and only single pill to combine three previously FDA-approved drugs – telmisartan, amlodipine, and indapamide – offering a triple-action approach for people who would otherwise need multiple pills to manage their blood pressure. It works in three ways and is a safe, well-tolerated early treatment option. Hypertension happens when your blood pushes too hard against your blood vessels, making the heart work harder and increasing the risk of heart problems, strokes, and other complications. It contributes to about 460,000 deaths annually in the U.S. and often goes undetected due to a lack of symptoms. With 1 in 3 Americans unaware they have it and only 1 in 4 managing it well, there's an urgent need for simpler, more effective treatments. The approval was based on two large studies that showed using Widaplik helped lower blood pressure more than using just two medicines or a placebo, according to a news release from the company that makes it, George Medicines. People who took Widaplik didn't stop taking it more often because of side effects, which means it was generally easy for them to take. Another trial showed that Widaplik was better at reducing blood pressure compared to standard care, while remaining well-tolerated. George Medicines stated that a global trial is underway to find out if the combo treatment can help prevent strokes in people who have previously had an intracerebral hemorrhage (sudden bleeding in the brain), the most serious type of stroke. "Single-pill combination antihypertensive therapy has great potential to improve hypertension control in the US and worldwide. Most patients with hypertension need multiple therapies to achieve their blood pressure goals. The new dose options available with Widaplik offer a treatment regimen that could benefit a broad range of patients, including those just starting treatment," Paul Whelton, MD, Show Chwan chair of global public health at Tulane University in New Orleans and past president of the World Hypertension League, said in a statement. Widaplik is a medicine made of three drugs that work together to help lower blood pressure. Two of them, telmisartan and amlodipine, relax blood vessels so blood can flow more easily. The third, indapamide, helps your body get rid of extra water by making you pee more. Widaplik comes in three strengths: 10/1.25/0.625 mg, 20/2.5/1.25 mg, and 40/5/2.5 mg. Low blood pressure – which can make you feel faint or dizzy – was the most common side effect, the company said. Patients who pass out should stop taking the medication and consult their doctor.